Prelude Therapeutics (NASDAQ:PRLD) Raised to “Hold” at Zacks Research

Prelude Therapeutics (NASDAQ:PRLD) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research analysts also recently issued reports on the company. Citizens Jmp lifted their price objective on Prelude Therapeutics from $3.00 to $6.00 and gave the stock a “market outperform” rating in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Thursday, January 22nd. HC Wainwright boosted their price target on Prelude Therapeutics from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday. Finally, Wall Street Zen downgraded Prelude Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.00.

Prelude Therapeutics Stock Up 9.4%

Shares of Prelude Therapeutics stock traded up $0.40 during trading on Tuesday, hitting $4.67. 147,376 shares of the company were exchanged, compared to its average volume of 377,847. Prelude Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $5.54. The stock has a market capitalization of $294.28 million, a price-to-earnings ratio of -3.62 and a beta of 0.73. The firm has a 50 day moving average price of $3.59 and a 200 day moving average price of $2.50.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.13. The company had revenue of $5.64 million for the quarter, compared to analyst estimates of $20.50 million.

Insider Buying and Selling at Prelude Therapeutics

In other Prelude Therapeutics news, Director David P. Bonita purchased 2,815,315 shares of the business’s stock in a transaction on Tuesday, April 21st. The stock was bought at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following the acquisition, the director owned 11,808,945 shares of the company’s stock, valued at approximately $52,431,715.80. The trade was a 31.30% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc purchased 2,815,315 shares of the business’s stock in a transaction on Tuesday, April 21st. The stock was acquired at an average price of $4.44 per share, with a total value of $12,499,998.60. Following the completion of the acquisition, the director directly owned 11,808,945 shares in the company, valued at $52,431,715.80. The trade was a 31.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 63.90% of the company’s stock.

Institutional Trading of Prelude Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in shares of Prelude Therapeutics by 170.7% in the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock worth $26,000 after buying an additional 21,330 shares during the period. Marshall Wace LLP acquired a new stake in Prelude Therapeutics during the second quarter worth about $34,000. XTX Topco Ltd increased its stake in Prelude Therapeutics by 72.4% during the second quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock worth $34,000 after acquiring an additional 17,873 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Prelude Therapeutics during the fourth quarter worth about $212,000. Finally, Shay Capital LLC acquired a new stake in Prelude Therapeutics during the second quarter worth about $61,000. 79.72% of the stock is currently owned by institutional investors and hedge funds.

Key Prelude Therapeutics News

Here are the key news stories impacting Prelude Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 EPS forecasts (Q1–Q4 and FY) and narrowed its FY2026 loss estimate to ($0.93) from ($1.24); the firm reiterated a Buy rating and an $8.00 price target — this is constructive because better-than-expected operating/earnings outlook and a high $8 PT increase the stock’s upside narrative. HC Wainwright raises estimates and reiterates Buy ($8 PT)
• Positive Sentiment: An outside report flagged a 19.35% increase in Prelude’s price target to $6.29 (reported 4/29) — another analyst/coverage update that supports higher near-term valuation expectations. PRLD price target increased to $6.29
• Neutral Sentiment: Zacks Research moved Prelude to a “hold” rating (not a downgrade to sell but not bullish), which mutes some of the upside momentum from other firms; Zacks’ current note and price reference are now part of the consensus view mix. Zacks upgrades Prelude to Hold

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.